JPMorgan upgrades Macerich stock rating on Path Forward progress

JPMorgan upgraded Macerich to Neutral from Underweight and raised its price target to $25 from $23, citing continued progress on the Path Forward plan and an approaching 2027/2028 earnings growth ramp. The company also announced an underwritten offering of 14 million shares at $23.90, with a 30-day option for 2.1 million more, while KeyBanc and Deutsche Bank also turned more constructive with $27 targets. Macerich continues to guide toward $600 million to $700 million of dispositions and givebacks in 2026-2027 and maintains a 2.86% dividend yield with 33 straight years of dividend payments.

Analysis

The signal is not the analyst upgrade itself; it is that the mall equity window has reopened just enough for balance-sheet repair to be executed at scale. A secondary at nearly the market price tells you management is willing to dilute near-term NAV to fund the next phase of the plan, which is usually constructive for creditors and long-duration landlords but can cap upside for equity until the capital is absorbed. In other words, the market is rewarding progress, but the trade is becoming less about turnaround optionality and more about whether the next 12-18 months can convert execution into per-share earnings rather than just gross earnings.

The second-order winner is likely the surviving Class A mall complex ecosystem: improved occupancy and traffic at a scaled operator can force weaker regional owners to keep funding concessions or accept lower-quality tenants. That matters for retail REIT peers with tighter balance sheets, because Macerich’s ability to fund accretive acquisitions while still disposing assets suggests a bifurcation in mall capital access — best-in-class platforms can consolidate, while smaller names face a higher cost of capital and shrinking tenant leverage. The implied read-through is mildly negative for weaker mall landlords, even if the headline is positive for the sector.

The main risk is timing. The market is already discounting a 2027/2028 earnings ramp, so any slip in leasing velocity, execution on dispositions, or a softer consumer backdrop would compress the multiple quickly because the stock has already rerated on future rather than current cash flow. The near-term dilution from the offering creates a window where upside may be limited for several quarters unless the company immediately demonstrates that new capital is translating into lower leverage and higher same-store productivity.

Key Decisions for Investors

• Avoid chasing MAC after the offering; wait 4-8 weeks for post-issuance digestion and look to add only if it holds above the deal price with improving volume and no concession in leasing metrics.
• Pair trade: long MAC / short a weaker regional mall REIT over 3-6 months to express consolidation winners vs capital-constrained losers; the spread should widen if leasing and asset-sale execution stays on track.
• For faster expression, buy MAC call spreads 6-9 months out rather than stock; upside is tied to 2027 expectations, but dilution and execution risk make defined-risk leverage preferable.
• Short basket idea: weak mall REITs with higher leverage and less access to capital; if MAC can fund growth while they cannot, tenant and lender share should migrate toward the stronger platform.
• Set a hard risk trigger on MAC if management revises 2026-2027 disposition targets lower or if forward-equity issuance continues; that would signal the balance-sheet story is still not self-funding.